Lipid oxidation by hypochlorous acid: Chlorinated lipids in atherosclerosis and myocardial ischemia

Clinical Lipidology

Volumn 5, Issue 6, 2010, Pages 835-852

  Ford, David A ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; fatty acid; fatty aldehyde; lipid; monocyte; myeloperoxidase; myocardial ischemia; neutrophil; plasmalogen

Indexed keywords

ALCOHOL DERIVATIVE; ALKENE; ALPHA CHLOROFATTY ACID; ALPHA CHLOROFATTY ALCOHOL; ALPHA CHLOROFATTY ALDEHYDE; ALPHA CHLOROHYDRIN; AMINE; CHLORINATED LIPID; HYPOCHLOROUS ACID; LIPID; LYSOPHOSPHATIDYLCHOLINE; MYELOPEROXIDASE; PLASMALOGEN; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; CHEMICAL REACTION; CHEMOTAXIS; ENZYME ACTIVITY; FATTY ACID METABOLISM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; LIPID OXIDATION; LIPID STORAGE; LIPOGENESIS; MACROPHAGE ACTIVATION; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; REVIEW;

RATTUS;

EID: 79952133271     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.68     Document Type: Review

References (133)

1. Han XL, Gross RW: Plasmenylcholine and phosphatidylcholine membrane bilayers possess distinct conformational motifs. Biochemistry 29(20), 4992-4996 (1990). (Pubitemid 20183766)
2. Hazen SL, Hall CR, Ford DA, Gross RW: Isolation of a human myocardial cytosolic phospholipase A2 isoform. Fast atom bombardment mass spectroscopic and reverse-phase high pressure liquid chromatography identification of choline and ethanolamine glycerophospholipid substrates. J. Clin. Invest. 91(6), 2513-2522 (1993). (Pubitemid 23182503)
3. Gross RW: High plasmalogen and arachidonic acid content of canine myocardial sarcolemma: a fast atom bombardment mass spectroscopic and gas chromatography-mass spectroscopic characterization. Biochemistry 23(1), 158-165 (1984). (Pubitemid 14181546)
4. Pike LJ, Han X, Chung KN, Gross RW: Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis. Biochemistry 41, 2075-2088 (2002). (Pubitemid 34132282)
5. Han X, Gross RW: Electrospray ionization mass spectroscopic analysis of human erythrocyte plasma membrane phospholipids. Proc. Natl Acad. Sci. USA 91(22), 10635-10639 (1994). (Pubitemid 24329053)
6. Post JA, Verkleij AJ, Roelofsen B, Op de Kamp JA: Plasmalogen content and distribution in the sarcolemma of cultured neonatal rat myocytes. FEBS Lett. 240(1-2), 78-82 (1988). (Pubitemid 19003902)
7. Gross RW: Identification of plasmalogen as the major phospholipid constituent of cardiac sarcoplasmic reticulum. Biochemistry 24(7), 1662-1668 (1985). (Pubitemid 15089159)
8. Zoeller RA, Grazia TJ, LaCamera P, Park J, Gaposchkin DP, Farber HW: Increasing plasmalogen levels protects human endothelial cells during hypoxia. Am. J. Physiol. Heart Circ. Physiol. 283(2), H671-H679 (2002). (Pubitemid 34790862)
9. Ford DA, Gross RW: Plasmenylethanolamine is the major storage depot for arachidonic acid in rabbit vascular smooth muscle and is rapidly hydrolyzed after angiotensin II stimulation. Proc. Natl Acad. Sci. USA 86(10), 3479-3483 (1989).
10. Malavolta M, Bocci F, Boselli E, Frega NG: Normal phase liquid chromatography-electrospray ionization tandem mass spectrometry analysis of phospholipid molecular species in blood mononuclear cells: Application to cystic fibrosis. J. Chromatogr. B 810(2), 173-186 (2004). (Pubitemid 39243303)
11. Chilton FH, Connell TR: 1-ether-linked phosphoglycerides. Major endogenous sources of arachidonate in the human neutrophil. J. Biol. Chem. 263(11), 5260-5265 (1988).
12. Chilton FH, Murphy RC: Remodeling of arachidonate-containing phosphoglycerides within the human neutrophil. J. Biol. Chem. 261(17), 7771-7777 (1986). (Pubitemid 17208700)
13. Vance JE: Lipoproteins secreted by cultured rat hepatocytes contain the antioxidant 1-alk-1-enyl-2-acylglycerophosphoethanolamine. Biochim. Biophys. Acta 1045(2), 128-134 (1990). (Pubitemid 20218821)
14. Corr PB, Saffitz JE, Sobel BE: Lysophospholipids, long chain acylcarnitines and membrane dysfunction in the ischaemic heart. Basic Res. Cardiol. 82(Suppl. 1), 199-208 (1987). (Pubitemid 17114095)
15. Corr PB, Gross RW, Sobel BE: Amphipathic metabolites and membrane dysfunction in ischemic myocardium. Circ. Res. 55(2), 135-154 (1984). (Pubitemid 14032930)
16. Kohno M, Yokokawa K, Yasunari K et al.: Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation 98(4), 353-359 (1998). (Pubitemid 28348058)
17. Quinn MT, Parthasarathy S, Steinberg D: Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Natl Acad. Sci. USA 85(8), 2805-2809 (1988).
18. Sartipy P, Hurt-Camejo E: Modification of plasma lipoproteins by group IIa phospholipase A(2): possible implications for atherogenesis. Trends Cardiovasc. Med. 9(8), 232-238 (1999).
19. McHowat J, Kell PJ, O'Neill HB, Creer MH: Endothelial cell paf synthesis following thrombin stimulation utilizes Ca(2+)-independent phospholipase A(2). Biochemistry 40(49), 14921-14931 (2001). (Pubitemid 33136113)
20. Uemura Y, Lee TC, Snyder F: A coenzyme A-independent transacylase is linked to the formation of platelet-activating factor (PAF) by generating the lyso-PAF intermediate in the remodeling pathway. J. Biol. Chem. 266(13), 8268-8272 (1991). (Pubitemid 21906507)
21. Venable ME, Nieto ML, Schmitt JD, Wykle RL: Conversion of 1-O-[3H] alkyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine to lyso platelet-activating factor by CoA-independent transacylase in membrane fractions of human neutrophils. J. Biol. Chem. 266(28), 18691-18698 (1991). (Pubitemid 21908139)
22. Ford DA, Gross RW: Identification of endogenous 1-O-alk-1′-enyl-2- acyl-sn-glycerol in myocardium and its effective utilization by choline phosphotransferase. J. Biol. Chem. 263(6), 2644-2650 (1988). (Pubitemid 18062904)
23. Ford DA, Gross RW: Differential accumulation of diacyl and plasmalogenic diglycerides during myocardial ischemia. Circ. Res. 64(1), 173-177 (1989). (Pubitemid 19028516)
24. Wolf RA, Gross RW: Identification of neutral active phospholipase C which hydrolyzes choline glycerophospholipids and plasmalogen selective phospholipase A2 in canine myocardium. J. Biol. Chem. 260(12), 7295-7303 (1985). (Pubitemid 15059367)
25. Ford DA, Gross RW: Activation of myocardial protein kinase C by plasmalogenic diglycerides. Am. J. Physiol. 258(1 Pt 1), C30-C36 (1990). (Pubitemid 20053592)
26. Ford DA, Miyake R, Glaser PE, Gross RW: Activation of protein kinase C by naturally occurring ether-linked diglycerides. J. Biol. Chem. 264(23), 13818-13824 (1989). (Pubitemid 19198475)
27. Morand OH, Zoeller RA, Raetz CR: Disappearance of plasmalogens from membranes of animal cells subjected to photosensitized oxidation. J. Biol. Chem. 263(23), 11597-11606 (1988).
28. Zoeller RA, Morand OH, Raetz CR: A possible role for plasmalogens in protecting animal cells against photosensitized killing. J. Biol. Chem. 263(23), 11590-11596 (1988).
29. Zoeller RA, Lake AC, Nagan N, Gaposchkin DP, Legner MA, Lieberthal W: Plasmalogens as endogenous antioxidants: somatic cell mutants reveal the importance of the vinyl ether. Biochem. J. 338 (Pt 3), 769-776 (1999). (Pubitemid 29140085)
30. Thompson DH, Inerowicz HD, Grove J, Sarna T: Structural characterization of plasmenylcholine photooxidation products. Photochem. Photobiol. 78(4), 323-330 (2003).
31. Stadelmann-Ingrand S, Favreliere S, Fauconneau B, Mauco G, Tallineau C: Plasmalogen degradation by oxidative stress: production and disappearance of specific fatty aldehydes and fatty a-hydroxyaldehydes. Free Radic. Biol. Med. 31(10), 1263-1271 (2001). (Pubitemid 33052502)
32. Klebanoff SJ, Waltersdorph AM, Rosen H: Antimicrobial activity of myeloperoxidase. Methods Enzymol. 105, 399-403 (1984). (Pubitemid 14165406)
33. Nathan C: Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 6(3), 173-182 (2006). (Pubitemid 43290987)
34. Davies MJ, Hawkins CL, Pattison DI, Rees MD: Mammalian heme peroxidases: From molecular mechanisms to health implications. Antioxid. Redox Signal 10(7), 1199-1234 (2008). (Pubitemid 351634397)
35. van der Veen BS, de Winther MP, Heeringa P: Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid. Redox Signal 11(11), 2899-2937 (2009).
36. Harrison JE, Schultz J: Studies on the chlorinating activity of myeloperoxidase. J. Biol. Chem. 251(5), 1371-1374 (1976).
37. Hazen SL, Hsu FF, Duffin K, Heinecke JW: Molecular chlorine generated by the myeloperoxidase-hydrogen peroxide-chloride system of phagocytes converts low density lipoprotein cholesterol into a family of chlorinated sterols. J. Biol. Chem. 271(38), 23080-23088 (1996). (Pubitemid 26314741)
38. Lampert MB, Weiss SJ: The chlorinating potential of the human monocyte. Blood 62(3), 645-651 (1983). (Pubitemid 13001698)
39. Heinecke JW, Li W, Mueller DM, Bohrer A, Turk J: Cholesterol chlorohydrin synthesis by the myeloperoxidase-hydrogen peroxide-chloride system: potential markers for lipoproteins oxidatively damaged by phagocytes. Biochemistry 33(33), 10127-10136 (1994). (Pubitemid 24286093)
40. Thomas EL, Jefferson MM, Grisham MB: Myeloperoxidase-catalyzed incorporation of amines into proteins: role of hypochlorous acid and dichloramines. Biochemistry 21(24), 6299-6308 (1982). (Pubitemid 13141634)
41. Winterbourn CC, van den Berg JJ, Roitman E, Kuypers FA: Chlorohydrin formation from unsaturated fatty acids reacted with hypochlorous acid. Arch. Biochem. Biophys. 296(2), 547-555 (1992).
42. Albert CJ, Crowley JR, Hsu FF, Thukkani AK, Ford DA: Reactive chlorinating species produced by myeloperoxidase target the vinyl ether bond of plasmalogens: Identification of 2-chlorohexadecanal. J. Biol. Chem. 276(26), 23733-23741 (2001).
43. Pattison DI, Hawkins CL, Davies MJ: Hypochlorous acid-mediated oxidation of lipid components and antioxidants present in low-density lipoproteins: absolute rate constants, product analysis, and computational modeling. Chem. Res. Toxicol. 16(4), 439-449 (2003). (Pubitemid 36514501)
44. Pattison DI, Davies MJ: Reactions of myeloperoxidase-derived oxidants with biological substrates: gaining chemical insight into human inflammatory diseases. Curr. Med. Chem. 13(27), 3271-3290 (2006). (Pubitemid 44669775)
45. Klebanoff SJ: Myeloperoxidase: contribution to the microbicidal activity of intact leukocytes. Science 169(950), 1095-1097 (1970).
46. Brennan ML, Anderson MM, Shih DM et al.: Increased atherosclerosis in myeloperoxidase-deficient mice. J. Clin. Invest. 107(4), 419-430 (2001). (Pubitemid 32167988)
47. Thong YH: How important is the myeloperoxidase microbicidal system of phagocytic cells? Med. Hypotheses 8(3), 249-254 (1982). (Pubitemid 12105776)
48. Chapman AL, Hampton MB, Senthilmohan R, Winterbourn CC, Kettle AJ: Chlorination of bacterial and neutrophil proteins during phagocytosis and killing of staphylococcus aureus. J. Biol. Chem. 277(12), 9757-9762 (2002). (Pubitemid 34968078)
49. Winterbourn CC, Hampton MB, Livesey JH, Kettle AJ: Modeling the reactions of superoxide and myeloperoxidase in the neutrophil phagosome: implications for microbial killing. J. Biol. Chem. 281(52), 39860-39869 (2006). (Pubitemid 46041789)
50. van Dalen CJ, Whitehouse MW, Winterbourn CC, Kettle AJ: Thiocyanate and chloride as competing substrates for myeloperoxidase. Biochem. J. 327(Pt 2), 487-492 (1997). (Pubitemid 27477827)
51. Berliner JA, Heinecke JW: The role of oxidized lipoproteins in atherogenesis. Free Radic. Biol. Med. 20(5), 707-727 (1996). (Pubitemid 26105783)
52. Marathe GK, Prescott SM, Zimmerman GA, McIntyre TM: Oxidized LDL contains inflammatory PAF-like phospholipids. Trends Cardiovasc. Med. 11(3-4), 139-142 (2001). (Pubitemid 33070337)
53. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88(6), 1785-1792 (1991).
54. Daugherty A, Dunn JL, Rateri DL, Heinecke JW: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94(1), 437-444 (1994). (Pubitemid 24218123)
55. Hazen SL, Heinecke JW: 3-chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest. 99(9), 2075-2081 (1997). (Pubitemid 27203762)
56. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R: Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J. Clin. Invest. 97(6), 1535-1544 (1996). (Pubitemid 26097044)
57. Malle E, Waeg G, Schreiber R, Grone EF, Sattler W, Grone HJ: Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur. J. Biochem. 267(14), 4495-4503 (2000). (Pubitemid 30461082)
58. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P: Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am. J. Pathol. 158(3), 879-891 (2001). (Pubitemid 32221781)
59. Podrez EA, Schmitt D, Hoff HF, Hazen SL: Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 103(11), 1547-1560 (1999).
60. Podrez EA, Poliakov E, Shen Z et al.: Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem. 277(41), 38503-38516 (2002). (Pubitemid 35154709)
61. Podrez EA, Poliakov E, Shen Z et al.: A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 277(41), 38517-38523 (2002). (Pubitemid 35154710)
62. Fu X, Kassim SY, Parks WC, Heinecke JW: Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J. Biol. Chem. 276(44), 41279-41287 (2001).
63. Zheng L, Nukuna B, Brennan ML et al.: Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114(4), 529-541 (2004). (Pubitemid 39572103)
64. Pennathur S, Bergt C, Shao B et al.: Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J. Biol. Chem. 279(41), 42977-42983 (2004). (Pubitemid 39372190)
65. Bergt C, Pennathur S, Fu X et al.: The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl Acad. Sci. USA 101(35), 13032-13037 (2004). (Pubitemid 39167578)
66. Shao B, Belaaouaj A, Verlinde CL, Fu X, Heinecke JW: Methionine sulfoxide and proteolytic cleavage contribute to the inactivation of cathepsin G by hypochlorous acid: an oxidative mechanism for regulation of serine proteinases by myeloperoxidase. J. Biol. Chem. 280(32), 29311-29321 (2005). (Pubitemid 41161386)
67. Shao B, Bergt C, Fu X et al.: Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J. Biol. Chem. 280(7), 5983-5993 (2005). (Pubitemid 40280082)
68. Shao B, Tang C, Heinecke JW, Oram JF: Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J. Lipid Res. 51(7), 1849-1858 (2010).
69. Thukkani AK, McHowat J, Hsu FF, Brennan ML, Hazen SL, Ford DA: Identification of a-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation 108(25), 3128-3133 (2003). (Pubitemid 38031803)
70. Thukkani AK, Albert CJ, Wildsmith KR et al.: Myeloperoxidase-derived reactive chlorinating species from human monocytes target plasmalogens in low density lipoprotein. J. Biol. Chem. 278(38), 36365-36372 (2003). (Pubitemid 37139964)
71. McMillen TS, Heinecke JW, LeBoeuf RC: Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation 111(21), 2798-2804 (2005). (Pubitemid 40791552)
72. Castellani LW, Chang JJ, Wang X, Lusis AJ, Reynolds WF: Transgenic mice express human mpo -463G/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in -463G males. J. Lipid Res. 47(7), 1366-1377 (2006). (Pubitemid 44079890)
73. Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A: Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematologica 104(1), 10-15 (2000).
74. Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA: A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am. Heart J. 142(2), 336-339 (2001). (Pubitemid 32706293)
75. Pecoits-Filho R, Stenvinkel P, Marchlewska A et al.: A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int. Suppl. 84, S172-S176 (2003). (Pubitemid 36513403)
76. Mocatta TJ, Pilbrow AP, Cameron VA et al.: Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J. Am. Coll. Cardiol. 49, 1993-2000 (2007). (Pubitemid 46734639)
77. Jordan JE, Zhao Z-Q, Vinten-Johansen J: The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc. Res. 43(4), 860-878 (1999). (Pubitemid 29413185)
78. Sheridan F, Dauber I, McMurtry I, Lesnefsky E, Horwitz L: Role of leukocytes in coronary vascular endothelial injury due to ischemia and reperfusion. Circ. Res. 69(6), 1566-1574 (1991).
79. Pabla R, Buda AJ, Flynn DM et al.: Nitric oxide attenuates neutrophil-mediated myocardial contractile dysfunction after ischemia and reperfusion. Circ. Res. 78(1), 65-72 (1996). (Pubitemid 26004122)
80. Engler R, Covell J: Granulocytes cause reperfusion ventricular dysfunction after 15-minute ischemia in the dog. Circ. Res. 61(1), 20-28 (1987). (Pubitemid 17123078)
81. Baldus S, Heeschen C, Meinertz T et al.: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108(12), 1440-1445 (2003). (Pubitemid 37176448)
82. Brennan ML, Penn MS, Van Lente F et al.: Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349(17), 1595-1604 (2003). (Pubitemid 37288567)
83. Zhang R, Brennan ML, Fu X et al.: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286(17), 2136-2142 (2001). (Pubitemid 34041599)
84. Marshall CJ, Nallaratnam M, Mocatta T et al.: Factors influencing local and systemic levels of plasma myeloperoxidase in ST-segment elevation acute myocardial infarction. Am. J. Cardiol. 106(3), 316-322 (2010).
85. Rudolph V, Andrié RP, Rudolph TK et al.: Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nature Med. 16(4), 470-474 (2010).
86. Lucchesi BR: Modulation of leukocyte-mediated myocardial reperfusion injury. Ann. Rev. Physiol. 52, 561-576 (1990). (Pubitemid 20103555)
87. Mehta J, Dinerman J, Mehta P et al.: Neutrophil function in ischemic heart disease. Circulation 79(3), 549-556 (1989). (Pubitemid 19087705)
88. Hayasaki T, Kaikita K, Okuma T et al.: CC chemokine receptor-2 deficiency attenuates oxidative stress and infarct size caused by myocardial ischemia-reperfusion in mice. Circulation J. 70(3), 342-351 (2006).
89. Ockaili R, Natarajan R, Salloum F et al.: HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am. J. Physiol. Heart Circ. Physiol. 289(2), H542-H548 (2005). (Pubitemid 41129367)
90. Litt MR, Jeremy RW, Weisman HF, Winkelstein JA, Becker LC: Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury. Circulation 80(6), 1816-1827 (1989). (Pubitemid 20031713)
91. Palazzo AJ, Jones SP, Anderson DC, Granger DN, Lefer DJ: Coronary endothelial P-selectin in pathogenesis of myocardial ischemia-reperfusion injury. Am. J. Physiol. 275(5 Pt 2), H1865-H1872 (1998).
92. Palazzo AJ, Jones SP, Girod WG, Anderson DC, Granger DN, Lefer DJ: Myocardial ischemia-reperfusion injury in CD18-and ICAM-1-deficient mice. Am. J. Physiol. 275(6 Pt 2), H2300-H2307 (1998).
93. Hansen PR: Role of neutrophils in myocardial ischemia and reperfusion. Circulation 91(6), 1872-1885 (1995).
94. Chen SY, Hsiao G, Hwang HR, Cheng PY, Lee YM: Tetramethylpyrazine induces heme oxygenase-1 expression and attenuates myocardial ischemia/reperfusion injury in rats. J. Biomed. Sci. 13(5), 731-740 (2006). (Pubitemid 44496873)
95. Duilio C, Ambrosio G, Kuppusamy P, DiPaula A, Becker LC, Zweier JL: Neutrophils are primary source of O2 radicals during reperfusion after prolonged myocardial ischemia. Am. J. Physiol. Heart Circ. Physiol. 280(6), H2649-H2657 (2001).
96. Shandelya SM, Kuppusamy P, Weisfeldt ML, Zweier JL: Evaluation of the role of polymorphonuclear leukocytes on contractile function in myocardial reperfusion injury. Evidence for plasma-mediated leukocyte activation. Circulation 87(2), 536-546 (1993). (Pubitemid 23040923)
97. Askari AT, Brennan ML, Zhou X et al.: Myeloperoxidase and plasminogen activator inhibitor-1 play a central role in ventricular modeling after myocardial infarction. J. Exp. Med. 197, 615-624 (2003). (Pubitemid 36314656)
98. Vasilyev N, Williams T, Brennan M-L et al.: Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 112(18), 2812-2820 (2005). (Pubitemid 41643823)
99. Thukkani AK, Martinson BD, Albert CJ, Vogler GA, Ford DA: Neutrophil-mediated accumulation of 2-ClHDA during myocardial infarction: 2-ClHDA-mediated myocardial injury. Am. J. Physiol. Heart Circ. Physiol. 288, H2955-H2964 (2005). (Pubitemid 40720680)
100. Kato K, Shao Q, Elimban V, Lukas A, Dhalla NS: Mechanism of depression in cardiac sarcolemmal Na+-K+-ATPase by hypochlorous acid. Am. J. Physiol. 275(3 Pt 1), C826-C831 (1998).
101. Okabe E, Takahashi S, Norisue M et al.: The effect of hypochlorous acid and hydrogen peroxide on coronary flow and arrhythmogenesis in myocardial ischemia and reperfusion. Eur. J. Pharmacol. 248(1), 33-39 (1993). (Pubitemid 23167685)
102. Persad S, Elimban V, Siddiqui F, Dhalla NS: Alterations in cardiac membrane b-adrenoceptors and adenylyl cyclase due to hypochlorous acid. J. Molec. Cell Cardiol. 31(1), 101-111 (1999). (Pubitemid 29078222)
103. Arnhold J, Osipov AN, Spalteholz H, Panasenko OM, Schiller J: Effects of hypochlorous acid on unsaturated phosphatidylcholines. Free Radic. Biol. Med. 31(9), 1111-1119 (2001). (Pubitemid 33000133)
104. Robaszkiewicz A, Greig FH, Pitt AR, Spickett CM, Bartosz G, Soszynski M: Effect of phosphatidylcholine chlorohydrins on human erythrocytes. Chem. Phys. Lipids 163(7), 639-647 (2010).
105. Spickett CM: Chlorinated lipids and fatty acids: an emerging role in pathology. Pharmacol. Ther. 115(3), 400-409 (2007). (Pubitemid 47362376)
106. Carr AC, van den Berg JJ, Winterbourn CC: Chlorination of cholesterol in cell membranes by hypochlorous acid. Arch. Biochem. Biophys. 332(1), 63-69 (1996). (Pubitemid 26286134)
107. Messner MC, Albert CJ, Hsu FF, Ford DA: Selective plasmenylcholine oxidation by hypochlorous acid: formation of lysophosphatidylcholine chlorohydrins. Chem. Phys. Lipids 144(1), 34-44 (2006). (Pubitemid 44537268)
108. Messner MC, Albert CJ, McHowat J, Ford DA: Identification of lysophosphatidylcholine- chlorohydrin in human atherosclerotic lesions. Lipids 43, 243-249 (2008).
109. Flemmig J, Spalteholz H, Schubert K, Meier S, Arnhold J: Modification of phosphatidylserine by hypochlorous acid. Chem. Phys. Lipids 161(1), 44-50 (2009).
110. Kawai Y, Kiyokawa H, Kimura Y, Kato Y, Tsuchiya K, Terao J: Hypochlorous acid-derived modification of phospholipids: characterization of aminophospholipids as regulatory molecules for lipid peroxidation. Biochemistry 45(47), 14201-14211 (2006). (Pubitemid 44846209)
111. Nusshold C, Kollroser M, Kofeler H et al.: Hypochlorite modification of sphingomyelin generates chlorinated lipid species that induce apoptosis and proteome alterations in dopaminergic PC12 neurons in vitro. Free Radic. Biol. Med. 48(12), 1588-1600 (2010).
112. Brahmbhatt VV, Hsu FF, Kao JL, Frank EC, Ford DA: Novel carbonyl and nitrile products from reactive chlorinating species attack of lysosphingolipid. Chem. Phys. Lipids 145(2), 72-84 (2007). (Pubitemid 46080415)
113. Leßig J, Schiller J, Arnhold J, Fuchs B: Hypochlorous acid-mediated generation of glycerophosphocholine from unsaturated plasmalogen glycerophosphocholine lipids. J. Lipid Res. 48, 1316-1324 (2007). (Pubitemid 47312033)
114. Thukkani AK, Hsu FF, Crowley JR, Wysolmerski RB, Albert CJ, Ford DA: Reactive chlorinating species produced during neutrophil activation target tissue plasmalogens: production of the chemoattractant, 2-chlorohexadecanal. J. Biol. Chem. 277(6), 3842-3849 (2002). (Pubitemid 34968634)
115. Marsche G, Heller R, Fauler G et al.: 2-chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler. Thromb. Vasc. Biol. 24(12), 2302-2306 (2004). (Pubitemid 39658033)
116. Skaff O, Pattison DI, Davies MJ: The vinyl ether linkages of plasmalogens are favored targets for myeloperoxidase-derived oxidants: a kinetic study. Biochemistry 47, 8237-8245 (2008).
117. Albrich JM, McCarthy CA, Hurst JK: Biological reactivity of hypochlorous acid: implications for microbicidal mechanisms of leukocyte myeloperoxidase. Proc. Natl Acad. Sci. USA 78(1), 210-214 (1981). (Pubitemid 11131267)
118. Heim WG, Appleman D, Pyfrom HT: Effects of 3-amino-1,2,4-triazole (AT) on catalase and other compounds. Am. J. Physiol. 186(1), 19-23 (1956).
119. Kukreja RC, Weaver AB, Hess ML: Stimulated human neutrophils damage cardiac sarcoplasmic reticulum function by generation of oxidants. Biochim. Biophys. Acta 990(2), 198-205 (1989). (Pubitemid 19055413)
120. Podrez EA, Abu-Soud HM, Hazen SL: Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic. Biol. Med. 28(12), 1717-1725 (2000). (Pubitemid 30628658)
121. Rausch PG, Moore TG: Granule enzymes of polymorphonuclear neutrophils: a phylogenetic comparison. Blood 46(6), 913-919 (1975).
122. Wildsmith KR, Albert CJ, Hsu FF, Kao JL-F, Ford DA: Myeloperoxidase- derived 2-chlorohexadecanal forms Schiff bases with primary amines of ethanolamine glycerophospholipids and lysine. Chem. Phys. Lipids 139, 157-170 (2006). (Pubitemid 43183738)
123. Wildsmith KR, Albert CJ, Anbukumar DS, Ford DA: Metabolism of myeloperoxidase-derived 2-chlorohexadecanal. J. Biol. Chem. 281, 16849-16860 (2006).
124. Rizzo WB, Craft DA, Dammann AL, Phillips MW: Fatty alcohol metabolism in cultured human fibroblasts. Evidence for a fatty alcohol cycle. J. Biol. Chem. 262(36), 17412-17419 (1987). (Pubitemid 18032217)
125. Anbukumar DS, Shornick LP, Albert CJ et al.: Chlorinated lipid species in activated human neutrophils: lipid metabolites of 2-chlorohexadecanal. J. Lipid Res. 51, 1085-1092 (2010).
126. Thomas EL, Bozeman PM, Jefferson MM, King CC: Oxidation of bromide by the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase. Formation of bromamines. J. Biol. Chem. 270(7), 2906-2913 (1995).
127. Weiss SJ, Test ST, Eckmann CM, Roos D, Regiani S: Brominating oxidants generated by human eosinophils. Science 234(4773), 200-203 (1986). (Pubitemid 17186098)
128. Albert CJ, Crowley JR, Hsu FF, Thukkani AK, Ford DA: Reactive brominating species produced by myeloperoxidase target the vinyl ether bond of plasmalogens: disparate utilization of sodium halides in the production of a-halo fatty aldehydes. J. Biol. Chem. 277(7), 4694-4703 (2002). (Pubitemid 34968500)
129. Albert CJ, Thukkani AK, Heuertz RM, Slungaard A, Hazen SL, Ford DA: Eosinophil peroxidase-derived reactive brominating species target the vinyl ether bond of plasmalogens generating a novel chemoattractant, a-bromo fatty aldehyde. J. Biol. Chem. 278(11), 8942-8950 (2003). (Pubitemid 36800371)
130. Ullen A, Fauler G, Kofeler H et al.: Mouse brain plasmalogens are targets for hypochlorous acid-mediated modification in vitro and in vivo. Free Radic. Biol. Med. DOI: 10.1016/j.freeradbiomed. 2010.08.025 (2010) (Epub ahead of print).
131. Carr AC, Vissers MC, Domigan NM, Winterbourn CC: Modification of red cell membrane lipids by hypochlorous acid and haemolysis by preformed lipid chlorohydrins. Redox Report 3(5-6), 263-271 (1997). (Pubitemid 28421136)
132. Iwase H, Yamada Y, Uemura H et al.: Effect of monochlorohydrins of linoleic acid on guinea-pig cardiac papillary muscles. Biochem. Biophys. Res. Comm. 231(2), 295-298 (1997). (Pubitemid 27214300)
133. Messner MC, Albert CJ, Ford DA: 2-chlorohexadecanal and 2-chlorohexadecanoic acid induce COX-2 expression in human coronary artery endothelial cells. Lipids 43(7), 581-588 (2008).